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The outbreak of antimicrobial resistance, together with the lack of newly developed
antimicrobial drugs, represents an alarming signal for both human and animal healthcare
worldwide. Selection of rational dosage regimens for traditional antimicrobial drugs
based on pharmacokinetic/pharmacodynamic principles as well as development of
novel antimicrobials targeting new bacterial targets or resistance mechanisms are key
approaches in tackling AMR. In addition to the cellular level resistance (i.e., mutation
and horizontal gene transfer of resistance determinants), the community level resistance
(i.e., bilofilms and persisters) is also an issue causing antimicrobial therapy difficulties.
Therefore, anti-resistance and antibiofilm strategies have currently become research
hotspot to combat antimicrobial resistance. Although metallic nanoparticles can both
kill bacteria and inhibit biofilm formation, the toxicity is still a big challenge for their clinical
applications. In conclusion, rational use of the existing antimicrobials and combinational
use of new strategies fighting against antimicrobial resistance are powerful warranties to
preserve potent antimicrobial drugs for both humans and animals.
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INTRODUCTION
Antimicrobial resistance (AMR) is one of the ultimate fears to the health of humans and animals
worldwide. Use of antimicrobial drugs in humans or animals results in the emergence and
dissemination of resistant bacteria, and overuse or abuse of them makes this situation worse. Thus,
it is important to simultaneously preserve effective antimicrobials as long as possible as well as
continue to employ them for the service of human and animal health (Chang et al., 2015).
The dissemination of AMR has not been paralleled by the development of novel antimicrobials.
This is due to that the process of drug discovery and clinical trials of new antimicrobials takes a
long time, and only a few new agents have recently been approved for use. These situations prompt
the efforts to develop alternatives to traditional antimicrobials, as described in our previous review
(Cheng et al., 2014). However, some of the alternatives are only used for the prevention of bacterial
infections (e.g., vaccines); some show indirect effect against pathogens (e.g., immunomodulators,
feed enzymes); some are of complex composition (e.g., probiotics, plant extracts), thus the effects
Abbreviations: AMR, antimicrobial resistance; HGT, horizontal gene transfer; MDR, multidrug-resistant; MIC, minimum
inhibitory concentration; NPs, nanoparticles; PK, pharmacokinetic; PD, pharmacodynamic; QS, quorum sensing; ROS,
reactive oxygen species.
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vary greatly; and the antimicrobial peptides, such as one of the
bacteriocins, lantibiotics, have been reported causing bacterial
resistance (Draper et al., 2015).
In this review, we briefly focus on old and novel antimicrobial
agents in tackling AMR. The AMR occurs on two levels,
the cellular level resistance (mutation and horizontal gene
transfer (HGT) of resistance determinants) and the community
level resistance (biofilm and persister cells) (Penesyan et al.,
2015). The studies reviewed suggest that only rational use of
existing old antimicrobial drugs and combinational use of anti-
resistance or antibiofilm strategies with antimicrobials as well as
continuing development of new antimicrobial agents could fight
against AMR.
MECHANISMS OF AMR
AMR includes two levels of resistance, the cellular level resistance
and the community level resistance (Penesyan et al., 2015;
Table 1). The development of cellular resistance occurs due to
endogenous gene mutations as well as via HGT of resistance
determinants from other microorganisms. Also, a group of
bacteria can be tolerant to the environmental stress that
individual cells cannot, which is called the community level
resistance. Such tolerance can cause an increased resistance to
antimicrobials (Penesyan et al., 2015). For example, the resistance
obtained by microorganisms in biofilm can be up to 1000 times
higher than that gained by their planktonic counterparts, which
impairs the treatment of biofilm-associated infections in clinical
treatment (Lebeaux et al., 2014b; Penesyan et al., 2015). The
main mechanism currently proposed to explain such tolerance
is the presence of persister cells. The persisters can escape the
lethal action of antimicrobials by entering a physiological state
in which the antimicrobials do not kill them, a phenomenon
known as bacterial persistence (Maisonneuve and Gerdes, 2014).
Moreover, the cellular and community levels of resistance can
be synergistic, thereby greatly enhancing the overall AMR of the
microbial community (Penesyan et al., 2015).
REVISIT TO OLD ANTIMICROBIALS
As AMR to commonly used antimicrobial drugs increases,
older antimicrobials are being “revived” and attracting attention.
These old antimicrobials represent a new alternative for the
control of AMR (Pulcini et al., 2012). Cassir et al. (2014)
have provided a collection of microbiological and clinical data
on potentially useful older antimicrobials for the successful
treatment of multidrug-resistant (MDR) Gram-negative bacterial
infections (e.g., polymyxins, fosfomycin, mecillinam, temocillin,
and nitrofurantoin), MDR Gram-positive infections (e.g.,
trimethoprim-sulfamethoxazole, tetracyclines, chloramphenicol,
clindamycin, pristinamycin, rifampicin, and fusidic acid), and
MDR tuberculosis (e.g., clofazimine, amoxicilline-clavulanate,
trimethoprim-sulfamethoxazole, and minocycline). Since older
antimicrobials have rarely been subjected to present drug
development procedures, they are less considered in practice
guidelines. Therefore, their efficacy and safety must be revaluated
to optimize therapy.
A number of antimicrobials discovered decades ago that have
unique chemical scaffolds and/or utilize novel modes of action
to interact with bacterial targets, such as ribosome (Arenz and
Wilson, 2016). For example, dityromycin, a cyclic decapeptide
antibiotic produced by Streptomyces sp., can uniquely bind
to ribosomal protein S12 in the small ribosomal subunit, a
mode of action different than any other known translational
inhibitor (Bulkley et al., 2014). In many cases, these “forgotten”
compounds display cytotoxicity against eukaryotic cells and
thus were abandoned (Arenz and Wilson, 2016). However,
recent structure-function analysis gives us better understanding
of the similarities and differences between bacterial targets
and their eukaryotic counterparts, thereby guiding the future
development of more specific and less toxic inhibitors. With
the increased understanding of AMR mechanisms, revisiting the
known antimicrobials are helpful to the exploration of the next
generation of antimicrobial drugs.
Procedures for registration of antimicrobials drugs have
improved significantly. Both EU (EMA, 2013) and US authorities
(FDA, 2010) have published numerous guidance documents,
and addressed the increasing need for antimicrobials that
are active against MDR bacteria. The guidance documents
include recommendations for dosage regimens based on
pharmacokinetic (PK)/pharmacodynamic (PD) relationships.
PK/PD provides a universal framework for exposure-response
relationships, and the responses include efficacy, toxicity, and
emergence of resistance (Muller et al., 2015). Exposure-response
relationships also provide a means to translate experimental
and preclinical data into the clinical settings, including setting
clinical breakpoints, as extensively described by the European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
(Mouton et al., 2012). To determine the optimal dose, several
key features of the exposure-response relationship need to
be determined, including MIC distribution of the interested
microorganisms, the PK profiles for a variety of doses and patient
populations, and the exposure-response relationship and PD
target (Muller et al., 2015).
There are knowledge gaps for those revived antimicrobials
in the areas of PK profiling in patients, as well as PD targets
derived from preclinical and clinical studies (Muller et al., 2015).
Although the regulatory requirements for new antimicrobial
agents have become more and more rigorous, updates of the
product information for old antimicrobials are either missing
or insufficient, which would pose significant risks of potential
harm to the patients. In addition, there is no motivation for
companies to develop antimicrobials when the cost and time of
drug approval is far beyond commercial interests, even if there is
an obvious medical need.
In summary, redevelopment of an old antimicrobials leads
to an improved understanding of its chemistry, PK/PD as well
as optimizing its clinical use in different patient populations.
Optimization of antimicrobial therapy in terms of PK/PD is
essential to improve therapeutic efficacy but minimize the
toxicity and the risk of resistance development during treatment
(Mouton et al., 2011). As old antimicrobials are rarely included
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TABLE 1 | Mechanisms of AMR (derived from Penesyan et al., 2015).
Mechanisms References
CELLULAR LEVEL RESISTANCE
Drug inactivation by hydrolysis (e.g., β-lactamase for β-lactam resistance) or modification (e.g.,
acetyltransferases for aminoglycoside resistance)
Shaw et al., 1993; Bush and Fisher, 2011
Target alteration by reducing the binding affinity to the drug (e.g., DNA gyrase mutation for
fluoroquinolone resistance) or bypassing the drug target
Hooper and Jacoby, 2015
Reducing drug influx by decreased permeability (e.g., the Gram-negative outer membrane) Nikaido, 2003
Drug extrusion via efflux pumps Li et al., 2015
HGT of resistance determinants from other microorganisms D’Costa et al., 2006
COMMUNITY LEVEL RESISTANCE
Biofilm matrix acts as a shield against antimicrobials (e.g., polysaccharides against aminoglycoside,
extracellular DNA against cationic peptides)
Mulcahy et al., 2008; Khan et al., 2010; Chiang et al., 2013
Antimicrobials targeting dividing bacteria have a limited effect against the slow or non-growing persisters Lewis, 2008, 2010
Starvation-induced stringent response caused by nutrient limitation in biofilm mediates high
biofilm-specific resistance
Nguyen et al., 2011; Bernier et al., 2013
SYNERGY BETWEEN COMMUNITY AND CELLULAR LEVEL RESISTANCE
Significantly enhanced mutation rate in biofilms leads to faster development of resistant mutants Conibear et al., 2009
Extracellular DNA in biofilm facilitates HGT of resistance determinants, encourages the acquisition and
exchange of resistant integron gene cassettes, and promotes conjugation and natural transformation
Blázquez, 2003; Townsend et al., 2003; Gillings et al., 2009;
Domingues et al., 2012
The sub-inhibitory concentration of antimicrobials in biofilm is favorable to increasing the rates of
mutation, recombination and HGT
Gillings and Stokes, 2012; Morita et al., 2014
Mechanisms of cellular level resistance can act in a biofilm-specific manner Zhang and Mah, 2008
in surveillance programs, the evaluation of the risks of drug
resistance is lacking. The prescription of old antimicrobials
needs to be regulated by professional antimicrobial stewardships.
Besides, as public health concern, cost effectiveness should be
integrated in further comparisons between old and currently
used antimicrobials.
DEVELOPMENT OF NEW
ANTIMICROBIALS
The current antimicrobials, mainly derived from natural
sources, inhibit cellular processes such as cell wall biosynthesis,
DNA replication, and protein synthesis. With the worldwide
emergence of AMR, there is renewed interest in the investigation
of alternative essential cellular processes, including bacterial
central metabolic pathways, as the drug targets for the next
generation of antimicrobials (Murima et al., 2014). For examples,
bedaquiline is an antitubercular drug targeting the F0F1 ATP
synthase (Andries et al., 2005). Like bedaquiline, Q203, an
optimized imidazopyridine amide compound, selectively inhibits
the respiratory cytochrome bc1 complex in mycobacteria
regardless of architectural conservation of the bc1 complex in
many species (Pethe et al., 2013). The inhibition of the bacterial
divisome, mainly by targeting the central cell division mediator
FtsZ, has been accepted as a promising strategy for antimicrobial
attack by either interfering with the natural dynamics and
functions of FtsZ during the cell cycle or activating a bacterial
protease to degrade FtsZ, thus causing bacterial death in a
suicidal manner (Sass and Brötz-Oesterhelt, 2013). The mode
of action of alkyl gallate is a combination of direct targeting of
FtsZ and permeabilization of bacterial membranes, which is a
promising hit for the further development of antibacterials (Król
et al., 2015). Recent efforts have also been devoted to developing
drugs that interrupt the assimilation of iron by bacteria, a process
that is vital to cellular homeostasis (Foley and Simeonov, 2012).
The unique asymmetric outer membrane in Gram-negative
bacteria, which acts as a permeability barrier that protects the cell
from external stresses such as the presence of antimicrobials, has
become an attractive drug target. A novel β-hairpin macrocyclic
peptide, JB-95, exhibits an ability to selectively disrupt the outer
membrane through interactions with selected β-barrel outer
membrane proteins including BamA and LptD, but not the
inner membrane of E. coli (Urfer et al., 2016). Furthermore, the
bacterial protein secretion pathway is a target for eliminating
or disarming pathogens. Targeting the Sec-pathway for novel
antimicrobial agents focuses on two key components: SecA, the
ATP-driven motor protein responsible for driving preproteins
across the cytoplasmic membrane and the Type I signal peptidase
which is responsible for the removal of the signal peptide to allow
the release of the mature protein from the membrane (Rao et al.,
2014).
Targeting resistance, usually used in combination with the
traditional antimicrobials, is another strategy to fight against
AMR. Among the four general resistance mechanisms, which
include target alteration (Hooper and Jacoby, 2015), drug
inactivation (Shaw et al., 1993; Bush and Fisher, 2011),
decreased permeability (Nikaido, 2003) and increased eﬄux
(Sun et al., 2014; Li et al., 2015), drug extrusion by multidrug
eﬄux pumps serves as an important mechanism of MDR.
Eﬄux pumps also have physiological functions in response
to various of environmental and physiological signals (Sun
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et al., 2014). Recent studies have tried to reverse the resistance
phenotype conferred by eﬄux pump activation (Opperman
and Nguyen, 2015; Venter et al., 2015). It was observed that
the addition of eﬄux pump inhibitors partially restored drug
susceptibility in vitro and in vivo in the anti-Mycobacterium
tuberculosis therapy (Pule et al., 2016). The class of zinc-
dependent hydrolases, metallo-β-lactamase, can confer bacteria
with extended spectrum β-lactam resistance. The design of
compounds with the β-lactam core scaffold is an attractive
approach to the development of metallo-β-lactamase inhibitors.
Some promising inhibitors, including cephalosporin derivatives,
penicillin derivatives, carbapenem derivatives, cyclobutanone
β-lactam analogs, thiol derivatives, succinic acid derivatives,
mercaptoacetic acid thioester derivatives, pyrrole-, pyridine-
and triazole-containing compounds, and DNA aptamer, have
been thoroughly reviewed by King and Strynadka (King and
Strynadka, 2013). Targeting the resistance mechanism itself by
a vaccine is an interesting but hitherto unexplored approach
(Henriques-Normark and Normark, 2014). Vaccination directed
against the resistance mechanism can be possible when resistance
is mediated by an enzyme whose activity can be inhibited by
neutralizing antibodies.
Except for the above inhibitors targeting resistance,
drugs in already-known classes such as new β-lactams,
quinolones, aminoglycosides, and tetracyclines have been
designed to escape from many of the known resistance
mechanisms. BAL30072, a siderophore monosulfactam similar
to aztreonam, exhibits antibacterial activity against most species
of aerobic Gram-negative bacteria (Page et al., 2010). It is
stable toward metallo-β-lactamases and is a poor substrate
for many serine carbapenemases. Several new quinolones,
such as avarofloxacin, delafloxacin, finafloxacin and the
desfluoroquinolone nemonoxacin, which show enhanced
activity against fluoroquinolone-resistant Gram-positive
bacteria including MRSA are in clinical development (Page
and Bush, 2014). A modified aminoglycoside, plazomicin,
has been demonstrated activity against both Gram-negative
and Gram-positive bacterial pathogens (Zhanel et al., 2012).
Modified tetracyclines, such as tigecycline, omadacycline and
eravacycline are of interest for their activity against many MDR
Enterobacteriaceae and Acinetobacter spp., including isolates
expressing tetracycline-specific eﬄux and ribosomal protection
proteins (Sutcliffe, 2011).
APPROACHES TO COMBAT BIOFILMS
The approaches to combat biofilms are extensively reviewed by
Beloin et al. (2014) (Table 2). During the biofilm development,
the bacteria initially adhere to a surface that ultimately leads
to colonization and infection by pathogenic bacteria. Therefore,
reducing adhesion is a strategy to prevent biofilm formation
and related infections (Veerachamy et al., 2014). Recently, non-
specific inhibition of adhesion vs. targeting specific adhesions has
been developed to reduce bacterial adhesion. Quorum sensing
(QS), which controls many important physiological processes
such as biofilm development, is a widespread intercellular form
of communicating and cooperative activities of bacteria at the
population level, and it depends on the production, secretion,
and detection of small diffusible autoinducers, such as acyl-
homoserine lactones, auto-inducing peptides and autoinducer
2 (Zhang and Li, 2016). Cyclic di-GMP is a second messenger
that acts to regulate a wide range of functions including
developmental transitions, adhesion and biofilm formation (Caly
et al., 2015). Targeting these signaling pathways is also a strategy
to prevent biofilm development. Moreover, using enzymes or
chelating agents can hydrolyze biofilm components or destabilize
biofilm matrix. On the other hand, persister cells have recently
been subjected to an intensive research in order to limit biofilm-
associated antimicrobial tolerance. The formation of persister
cells depends on the ubiquitous bacterial regulatory nucleotides
tetra and penta-guanosine phosphate (ppGpp) that activate
inhibitors of cell growth (Germain et al., 2015). Therefore,
interfering ppGpp could inhibit the formation of persister cells.
The deep research on the mechanism of biofilm formation
leads to the emergence of numerous promising antibiofilm
approaches. However, the conversion of experimental data
into clinical settings is time-consuming and to some extent
unsatisfactory. Non-biocidal anti-adhesive or anti-virulence
strategies face the diversity of bacterial phenotypes and may only
be active against a subpopulation of bacteria encountered in
clinical practice, therefore limiting their overall efficacy. In vitro
biofilms are probably structurally different from in vivo biofilms
(Lebeaux et al., 2013). Currently, due to the diversity of the in vivo
conditions leading to the complexity of clinical biofilm situations,
the diversity of persister phenotypes is unknown. Most of the
studies use rodent models, but these in vivo models may not
properly replicate real clinical state. Furthermore, as for clinical
trials, rigorous statistical analysis is compulsory in order to avoid
any false positive results. Most importantly, molecules identified
in vitro should be validated using in vivomodels not only for the
antibiofilm activity but also non-toxicity.
METALLIC NANOPARTICLES (NPS)
Physiochemical properties of nanomolecules as antimicrobial
agents are widely used in human and veterinary medicine.
Metallic NPs are of great interest for use as potential
antimicrobial agents because of their unique optical, electronic,
and magnetic properties (Kandi and Kandi, 2015). The
electrostatic interaction of NPs with negatively charged bacterial
surfaces draws the particles to the bacteria and promotes their
penetration into the membrane, causing membrane disruption,
bacterial flocculation, and a reduction in viability. The generation
of reactive oxygen species (ROS) is also a mechanism of
antibacterial activity of NPs (Thekkae Padil and Cˇerník, 2013).
Further actions of NPs as antimicrobial agents include disrupting
DNA during the replication and cell division of microorganisms,
compromising the bacterial membrane integrity via physical
interactions with the microbial cell, and releasing toxic metal
ions and causing lysis of cells (Franci et al., 2015). Recently,
the silicon dioxide NPs (Si-NP) were engineered to target the
signaling molecules (i.e., acylhomoserine lactones) used for QS
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TABLE 2 | Recent studies of some promising antibiofilm strategies.
Mode of actions Categories Reported approaches References
Non-specific
anti-adhesion
Anti-adhesive
polymers
Polymers comprising ester and cyclic hydrocarbon moieties reduced the attachment of
E. coli, P. aeruginosa and S. aureus
Hook et al., 2012
Vascular catheters with a non-leaching poly-sulfobetaine surface modification reduced the
adhesion of E. coli and S. aureus
Smith et al., 2012
Methyl-cellulose-coated totally implantable venous access ports implanted in rats inhibited
the adhesion of P. aeruginosa and S. aureus
Chauhan et al., 2014
Dental adhesives containing dimethylaminododecyl methacrylate inhibited S. mutans,
S. gordonii, and S. sanguinis multispecies biofilms
Zhang et al., 2015
Specific
anti-adhesion
Impeding adhesion
biogenesis
AL1 targeted the subunit polymerization of the type 1 pilus assembly, thus disrupted the
pilus-dependent biofilm formation in uropathogenic E. coli.
Lo et al., 2014
Lectins competitors Inhibitors of the type 1 fimbriae adhesion prevented catheter-associated urinary tract
infections and chronic cystitis in mice infected by E. coli
Totsika et al., 2013
Targeting virulence
factor
Limonene showed antibiofilm activity against S. pyogenes, S. mutans and S. mitis by
downregulation of the surface-associated virulence factor genes
Subramenium et al., 2015
Bulky hydrocarbons Maltose derivatives with bulky hydro-carbon groups exhibited an inhibition of
adhesins/receptors mediated binding of P. aeruginosa
Shetye et al., 2014
Targeting signaling
pathways
Interfering
cyclic-di-GMP
Inhibitors of diguanylate cyclase enzymes that synthesize cyclic-di-GMP inhibited the
biofilm formation by Vibrio cholerae
Sambanthamoorthy et al.,
2012
Interfering QS Analogs of QS autoinducers or enzymes degrading QS molecules were used to quench
QS-controlling biofilm formation
Zhu and Kaufmann, 2013;
Rampioni et al., 2014
Inhibitors of the quorum regulator, the staphylococcal accessory regulator A (SarA),
showed antibiofilm activity against S. aureus
Balamurugan et al., 2015
Dispersing biofilm
matrix
Enzymes Degradation of extracellular DNA by DNaseI or hydrolyzing poly-N-acetylglucosamine by
Dispersin B dispersed biofilms in vitro and in vivo
Darouiche et al., 2009;
Hymes et al., 2013
Phage depolymerases can degrade the extracellular polymers to allow the permeation of
bacteriophages into deeper biofilm layers to kill bacteria
Parasion et al., 2014
Chelating agents EDTA was an efficient adjuvant to gentamicin to eradicate E. coli, P. aeruginosa, S. aureus
and S. epidermidis biofilms and persisters
Banin et al., 2006; Chauhan
et al., 2012
Fighting persisters Inhibiting persister
formation
The ppGpp analog, relacin, inhibited the B. subtilis RelA synthetase activity and biofilm
formation
Wexselblatt et al., 2012,
2013
Peptide 1018 displayed a specific antibiofilm activity against P. aeruginosa and S. aureus
by inducing ppGpp degradation
de la Fuente-Núñez et al.,
2014
Art-175, an artilysin covalently combined a bacteriophage-encoded endolysin can pass
the outer membrane to kill P. aeruginosa persisters
Briers et al., 2014
Potentiating
antimicrobials
Sugar metabolic stimuli potentiated aminoglycoside against E. coli and S. aureus
persisters by facilitating aminoglycoside uptake
Allison et al., 2011
Silver potentiated antimicrobials against bacterial biofilm and persisters by increasing ROS
production and bacterial permeability to antimicrobials
Morones-Ramirez et al.,
2013
Raising pH by using basic amino acids (e.g., L-arginine) potentiated aminoglycosides
activity against E. coli and S. aureus persisters
Lebeaux et al., 2014a
Inactivating
tolerance
AHL QS inhibitors, brominated furanones, could revert antimicrobial tolerance of
P. aeruginosa and E. coli persisters
Pan and Ren, 2013
Combining the acyldepsipeptide antibiotic that activates ClpP with rifampicin led to
complete eradication of S. aureus biofilms
Conlon et al., 2013
in order to halt bacterial communication (Miller et al., 2015).
The bactericidal activity of NPs depends on size, stability and
concentration in the growth medium (Tillotson and Theriault,
2013). The applications of nanomolecules in medicine have
recently been evaluated in reports highlighting the in vitro
antimicrobial activities of NPs (Table 3), and also the possible
potential adverse effects of nanomolecules on human health and
the environment (Kandi and Kandi, 2015).
As various metallic NPs and their oxides have already been
used as potent antimicrobial agents, silver or ionic form is most
toxic for microorganisms when compared to other metals (Seil
and Webster, 2012). This makes silver of particularly interests.
Silver NPs (AgNPs) probably have multiple mechanisms of
antibacterial action (Markowska et al., 2013). For example, (1)
AgNPs can affect bacterial membrane permeability by attaching
to the cell membrane surface and modifying the cell potential;
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TABLE 3 | Selected studies on the antibacterial activity of metallic
nanoparticles.
Nanoparticles Target organisms References
Au-zeolites NPs E. coli
Salmonella typhi
Lima et al., 2013
PAH capped AuNPs and
AgNPs
Bacillus Calmette-Guérin
E. coli
Zhou et al., 2012
AgNPs Microcystis aeruginosa El-Sheekh and
El-Kassas, 2014
AgNPs Enterococcus hirae Vardanyan et al., 2015
AgNPs/halloysite
nanotubes/graphene
nanocomposites
(Ag/HNTs/rGO)
E. coli
S. aureus
Yu et al., 2014
Selenium and AgNPs
produced by Bacillus
E. coli
S. aureus
Klebsiella spp.
Pseudomonas spp.
Singh et al., 2014
AgNO3 NPs produced
by Allium sp
E. coli
Proteus spp.
Klebsiella spp.
Staphylococcus spp.
Enterobacter spp.
Bacillus spp.
Pseudomonas spp.
Lekshmi et al., 2012;
Aramwit et al., 2014;
El Kassas and Attia,
2014
ZnO NPs E. coli
P. aeruginosa
Aspergillus niger
Salmonella choleraesuis
S. aureus
Azizi et al., 2013;
Chitra and Annadurai,
2013
ZnO, CuO, and Fe2O3
NPs
S. aureus
B. subtilis
P. aeruginosa
E. coli
Azam et al., 2012
Polyacrylamide-doped
Fe3O4 NPs
E. coli Mukherje, 2014
Ag-implanted Ti NPs Streptococcus mutans
Porphyromonas gingivalis
Candida albicans
Zheng et al., 2012
H2TiO3 and SiO2 NPs E. coli
S. aureus
Enterococcus faecalis
Candida sp.
Krokowicz et al., 2015
Polymethyl methacrylate
denture acrylic loading
PtNPs
S. mutans
S. sobrinus
Nam, 2014
(2) AgNPs can causes oxidative damage by production of ROS
(Kim et al., 2007; Xu et al., 2012); (3) AgNPs can interact with
the SH-groups of bacterial membrane proteins and intracellular
proteins, and also can interact with the phosphate residues in
TABLE 4 | Selected studies on the antibiofilm activity of AgNPs.
Diameter (nm) Biofilm of microorganisms References
65 ± 30 nm P. putida Fabrega et al., 2009
50 nm P. aeruginosa
S. epidermidis
Kalishwaralal et al.,
2010
25.2 ± 4 nm P. aeruginosa (also kill the
bacteria)
Martinez-Gutierrez
et al., 2013
20∼30 nm Sensitive strain of P. aeruginosa
(inhibition rate of 67%)
Multidrug resistant strain of P.
aeruginosa (inhibition rate of 56%)
Palanisamy et al.,
2014
5∼8 and 16∼19 nm Salmonella enteritidis, S. hadar,
and S. Senftenberg
Losasso et al., 2014
12.6 ± 5.7 nm Mycobacterium spp. (reduce
survival of this bacterium to only
0.03%)
Islam et al., 2013
2.7 ± 0.6 nm (used
for dental
composites)
Oral bacteria S. mutans Cheng et al., 2012
47 nm
(citrate-capped)
P. aeruginosa Park et al., 2013
20 nm (silver coated
polyvinyl pyrrolidone)
Streptococcus pneumoniae Bibbs et al., 2014
20 nm
(starch-stabilized)
P. aeruginosa
S. aureus
Mohanty et al., 2012
10 nm (used to coat
the surface of
catheters)
(complete inhibition)
E. coli
S. aureus
Candida albicans (more than 50%
inhibition)
Enterococcus sp.
coagulase-negative staphylococci
P. aeruginosa
Roe et al., 2008
8 nm (hydrolyzed
casein peptide-
stabilized)
E. coli
P. Aeruginosa
Serratia proteamaculans
Radzig et al., 2013
4–7 nm
(β-cyclodextrin-
stabilized)
S. epidermidis CSF 41498 Jaiswal et al., 2015
1.9∼4.3 nm
(microwave
accelerated and
Eucalyptus globulus
leaf extract-stabilized)
S. aureus (MRSA)
S. aureus (MSSA)
P. aeruginosa (ESBL)
Ali et al., 2015
DNA, thus to interfere with protein synthesis and function and
cell division (Durán et al., 2016). However, due to the current
lack of knowledge, the exact basis for the activity of AgNPs is still
uncharacterized.
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The antibiofilm activity of AgNPs has also been demonstrated
in a number of studies (Table 4). Most of the AgNPs are
within the range of 1∼100 nm. Although smaller AgNPs
may have greater biological activity, it is important to note
that differences in the chemical and physical properties of
AgNP may cause variation in its antimicrobial and antibiofilm
efficacy (Markowska et al., 2013). Because of the relatively
low stability of colloidal solutions, some researchers propose
the usage of stabilized AgNPs (Table 4). AgNPs can also
enhance the antibacterial and antibiofilm activity of conventional
antimicrobials. There are reports describing synergistic activity
between AgNPs and, e.g., ampicillin, kanamycin, streptomycin
or vancomycin against E. coli and P. aeruginosa (Wolska et al.,
2012). Some AgNPs have been subjected to clinical trials (Franci
et al., 2015).
Although metallic NPs have great potential in the future
to become antimicrobial agents, the local and systemic
toxic complications and the deleterious effect they have on
beneficial bacteria in humans and animals may be a cause
for concern (Zhang et al., 2010; Prabhu and Poulose, 2012).
NPs have the ability to spread throughout the body, cross
the blood-brain barrier, cause haemolysis, and may result in
degradation products which have toxic effects and influence
blood coagulation pathways (Kandi and Kandi, 2015). Most
studies have not conclusively evaluated the exact mechanism
by which nanomolecules contribute to toxic complications, and
many of the interactions of the AgNPs with the human or animal
body are still poorly understood (dos Santos et al., 2013). It has
been observed that the larger size of NP, the greater is the risk
of adverse health effects (De Jong and Borm, 2008). Research is
necessary to clearly understand the interaction of nanomolecules
with living cells, the extent of their distribution in the body, and
their specific organ toxicity.
CONCLUDING REMARKS
The paradox of antimicrobial drugs is that through their use, they
not only inhibit an infection but also select for the emergence
and spread of AMR, directly counteracting their long-term
efficacy. Considerable inappropriate use of both prophylactic and
therapeutic antimicrobials in human and veterinary medicine
highlights an urgent need for antibiotic stewardship initiatives.
At the present time, rational use of existing antibiotics based
on PK/PD dosage-regimen is a key strategy in tackling AMR,
thus to preserve potent antimicrobials for both humans and
animals. At the same time, we should never stop discovering
novel inhibitors with new bacterial targets and digging the
treasure box of “old” and “forgotten” antimicrobials. Compounds
showing profound anti-resistance and antibiofilm effects are
in research hotspot, but they still have limitations. Combining
existing antimicrobials with compounds that inhibit their specific
resistance mechanisms would be a good choice. Although
metallic NPs can both kill bacteria and inhibit biofilm formation,
the toxicity is still a big challenge for their clinical applications
(dos Santos et al., 2013). With single-drug therapy, there is
always a selective advantage to resistance; specific combinations
of drugs can inhibit bacterial growth while disfavoring resistance
to the individual components. These approaches can be used
to invert the selective advantage of resistant bacteria competing
with their sensitive cousins, or even drive a resistant bacterial
population back toward drug sensitivity (Baym et al., 2016).
Besides, screening and developing multiple-target inhibitors
as “resistance-resistant” antimicrobials can reduce the effects
of target mutation (Oldfield and Feng, 2014). The natural
products have also been a prolific and unsurpassed source for
new lead antimicrobial compounds, but target identification
and validation has remained a major bottleneck (Farha and
Brown, 2016). Functional genomics techniques are proved
to be indispensible for in vitro target authentication and
elucidating mechanism of action of novel antimicrobials (Khan
and Khan, 2016). Since most of the new strategies described
in this review are only at the early basic experimental stage,
their potential for clinical applications requires more extensive
investigations.
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